Progress in Medicinal Chemistry
- 1st Edition, Volume 59 - April 30, 2020
- Imprint: Elsevier
- Editors: David R. Witty, Brian Cox
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 1 1 7 3 - 1
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 1 1 7 4 - 8
Progress in Medicinal Chemistry, Volume 59, provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors,… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteProgress in Medicinal Chemistry, Volume 59, provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors, with this release focusing on Small Molecules - Giant Leaps for Immuno-Oncology, Reviewing P2X7, Reviewing ASK1, and Reviewing DNA-encoded libraries.
- Provides extended, timely reviews of topics in medicinal chemistry
- Contains targets and technologies relevant to the discovery of tomorrow’s drugs
- Presents analyses of successful drug discovery programs
Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes
- Small molecules—Giant leaps for immuno-oncology
- P2X7 receptor antagonists for the treatment of systemic inflammatory disorders
- Discovery and development of ASK1 inhibitors
- An overview of DNA-encoded libraries—A versatile tool for drug discovery
Lisa Kötzner, Bayard Huck, Sakshi Garg and Klaus Urbahns
Christine F. Gelin, Anindya Bhattacharya and Michael A. Letavic
Reginald Brys, Karl Gibson, Tanja Poljak, Steven Van Der Plas and David Amantini
Daniel Madsen, Carlos Azevedo, Iolanda Micco, Lars Kolster Petersen and Nils Jakob Vest Hansen
- Edition: 1
- Volume: 59
- Published: April 30, 2020
- No. of pages (Hardback): 260
- No. of pages (eBook): 260
- Imprint: Elsevier
- Language: English
- Hardback ISBN: 9780128211731
- eBook ISBN: 9780128211748
DW
David R. Witty
Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.
In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.
David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.
Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.
Affiliations and expertise
WITNET LTD, Cambridge, UKBC
Brian Cox
Professor Brian Cox is at University of Sussex, Brighton, UK
Affiliations and expertise
Professor, University of Sussex, Brighton, UKRead Progress in Medicinal Chemistry on ScienceDirect